Indivior PLC (NASDAQ:INDV) Shares Sold by Mackenzie Financial Corp

Mackenzie Financial Corp decreased its holdings in shares of Indivior PLC (NASDAQ:INDV) by 2.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 550,640 shares of the company’s stock after selling 11,955 shares during the quarter. Mackenzie Financial Corp’s holdings in Indivior were worth $8,305,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in INDV. Geode Capital Management LLC acquired a new stake in Indivior during the second quarter worth $2,510,000. Royal Bank of Canada acquired a new stake in Indivior during the second quarter worth $915,000. Goldman Sachs Group Inc. acquired a new stake in shares of Indivior in the second quarter valued at $83,678,000. State of Tennessee Treasury Department acquired a new stake in shares of Indivior in the second quarter valued at $2,150,000. Finally, Wells Fargo & Company MN acquired a new stake in shares of Indivior in the second quarter valued at $34,000. Institutional investors and hedge funds own 60.33% of the company’s stock.

Analysts Set New Price Targets

Separately, Craig Hallum initiated coverage on Indivior in a research note on Wednesday, April 3rd. They issued a “buy” rating and a $37.00 price objective for the company.

Indivior Trading Down 1.3 %

Shares of NASDAQ INDV opened at $18.52 on Friday. Indivior PLC has a twelve month low of $14.38 and a twelve month high of $26.50. The stock has a fifty day simple moving average of $20.45 and a 200-day simple moving average of $18.40. The stock has a market capitalization of $2.55 billion, a PE ratio of -925.54 and a beta of 0.46.

Indivior (NASDAQ:INDV) last issued its quarterly earnings data on Thursday, February 22nd. The company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.28 by $0.15. The business had revenue of $293.00 million during the quarter, compared to analysts’ expectations of $260.00 million. Indivior had a return on equity of 538.18% and a net margin of 0.18%. On average, equities analysts predict that Indivior PLC will post 2.03 earnings per share for the current year.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.